Pluripotent Human Stem Cells A Novel Tool in Drug Discovery

被引:17
|
作者
Phillips, Blaine W. [2 ]
Crook, Jeremy M. [1 ]
机构
[1] OBrien Inst, Melbourne, Vic 3065, Australia
[2] ASTAR, Inst Med Biol, Singapore, Singapore
关键词
IN-VITRO; CARDIOMYOCYTE DIFFERENTIATION; HUMAN FIBROBLASTS; HIGHLY EFFICIENT; GENE-EXPRESSION; CARDIAC SAFETY; GENERATION; HEPATOCYTES; CULTURE; INDUCTION;
D O I
10.2165/11532270-000000000-00000
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
The need for new and improved pharmacotherapies in medicine, high late-stage compound attrition in drug discovery, and upcoming patent expirations is driving interest by the pharmaceutical industry in pluripotent stem cells for in vitro modeling and early-stage testing of toxicity and target engagement. In particular, human embryonic and induced pluripotent stem cells represent potentially cost-effective and accessible sources of organ-specific cells that foretell in vivo human tissue response to new chemical entities. Here we consider the potential of these cells as novel tools for drug development, including toxicity screening and metabolic profiling. We hold that despite various challenges to translating proof-of-concept screening platforms to industrial use, the promise of research is considerable, and close to being realized.
引用
收藏
页码:99 / 108
页数:10
相关论文
共 50 条
  • [32] Disease-specific induced pluripotent stem cells: a platform for human disease modeling and drug discovery
    Jiho Jang
    Jeong-Eun Yoo
    Jeong-Ah Lee
    Dongjin R Lee
    Ji Young Kim
    Yong Jun Huh
    Dae-Sung Kim
    Chul-Yong Park
    Dong-Youn Hwang
    Han-Soo Kim
    Hoon-Chul Kang
    Dong-Wook Kim
    Experimental & Molecular Medicine, 2012, 44 : 202 - 213
  • [33] Human Pluripotent Stem Cells for Modeling of Anticancer Therapy-Induced Cardiotoxicity and Cardioprotective Drug Discovery
    Keung, Wendy
    Cheung, Yiu-Fai
    FRONTIERS IN PHARMACOLOGY, 2021, 12
  • [34] Disease-specific induced pluripotent stem cells: a platform for human disease modeling and drug discovery
    Jong, Jiho
    Yoo, Jeong-Eun
    Lee, Jeong-Ah
    Lee, Dongjin R.
    Kim, Ji Young
    Huh, Yong Jun
    Kim, Dae-Sung
    Park, Chul-Yong
    Hwang, Dong-Youn
    Kim, Han-Soo
    Kang, Hoon-Chul
    Kim, Dong-Wook
    EXPERIMENTAL AND MOLECULAR MEDICINE, 2012, 44 (03): : 202 - 213
  • [35] Cardiomyocytes from human pluripotent stem cells: the new patient in safety pharmacology, drug discovery and disease
    Mummery, C. L.
    EUROPEAN JOURNAL OF CLINICAL INVESTIGATION, 2014, 44 : 5 - 5
  • [36] Pluripotent Stem Cell Platforms for Drug Discovery
    Chen, Kevin G.
    Mallon, Barbara S.
    Park, Kyeyoon
    Robey, Pamela G.
    McKay, Ronald D. G.
    Gottesman, Michael M.
    Zheng, Wei
    TRENDS IN MOLECULAR MEDICINE, 2018, 24 (09) : 805 - 820
  • [37] Induced Pluripotent HD Monkey Stem Cells Derived Neural Cells for Drug Discovery
    Kunkanjanawan, Tanut
    Carter, Richard
    Ahn, Kwan-Sung
    Yang, Jinjing
    Parnpai, Rangsun
    Chan, Anthony W. S.
    SLAS DISCOVERY, 2017, 22 (06) : 696 - 705
  • [38] Human induced pluripotent stem cells as a tool for disease modeling and drug screening for COVID-19
    Nolasco, Patricia
    Borsoi, Juliana
    Moraes, Carolina Borsoi
    Freitas-Junior, Lucio H.
    Pereira, Lygia Veiga
    GENETICS AND MOLECULAR BIOLOGY, 2020, 44 (01) : 1 - 8
  • [39] Human pluripotent stem cell–based cardiovascular disease modeling and drug discovery
    Ge Liu
    Zhun Liu
    Nan Cao
    Pflügers Archiv - European Journal of Physiology, 2021, 473 : 1087 - 1097
  • [40] Human pluripotent-stem-cell-derived organoids for drug discovery and evaluation
    Vandana, J. Jeya
    Manrique, Cassandra
    Lacko, Lauretta A.
    Chen, Shuibing
    CELL STEM CELL, 2023, 30 (05) : 571 - 591